Acebilustat

Phase 2Small molecule

SStanford University

Acebilustat is one of 2 small molecule programs targeting Lymphedema. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphedemaActive, not recruiting

LymphedemaPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Lymphedema

#DrugCompanyPhaseTrials

Acebilustat

SStanford University

Phase 2

1 2

GLP-1 Receptor Agonists

JJinling Hospital, China

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-192 trials

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

Completed·SStanford University·Phase 2·NCT04662086·122 enrolled

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol

Completed·SStanford University·Phase 2·NCT04662060·120 enrolled

Lymphedema1 trial

Trial of Acebilustat for the Treatment of Upper Arm Lymphedema

Active, not recruiting·SStanford University·Phase 2·NCT05203835·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Acebilustat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acebilustat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acebilustat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SStanford University

Acebilustat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-192 trials

Lymphedema1 trial

References

Drug Info

Quick Facts

Related News